This is a multi-center, long-term safety and efficacy follow-up study for participants with cerebral adrenoleukodystrophy (CALD) who have received Lenti-D Drug Product (eli-cel) in a parent clinical study (Study ALD-102 or Study ALD-104). After completing a parent clinical study (approximately 2 years), eligible participants will be followed for an additional 13 years for a total of 15 years post-drug product infusion. No investigational drug product will be administered in this study.
Age range
19 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Major functional disability (MFD)-free survival
Timeframe: 15 years post-drug-product infusion
Number of participants with malignancies
Timeframe: 15 years post-drug-product infusion
Number of participants who experience graft versus host disease (GVHD)
Timeframe: 15 years post-drug-product infusion
Number of participants with immune-related adverse events (AEs)
Timeframe: 15 years post-drug-product infusion
Number of participants with new or worsening hematologic disorders
Timeframe: 15 years post-drug-product infusion
Number of participants with new or worsening neurologic disorders
Timeframe: 15 years post-drug-product infusion